Department of Cardiology, Santa Maria del Carmine Hospital, Corso Verona 4, 38068 Rovereto-TN, Italy.
Europace. 2018 Jun 1;20(6):1050-1057. doi: 10.1093/europace/eux187.
Implantable loop recorders (ILR) are indicated in a variety of clinical situations when extended cardiac rhythm monitoring is needed. We aimed to assess the clinical impact, safety, and accuracy of the new Medtronic Reveal LINQTM ILR that can be inserted outside the electrophysiology (EP) laboratory and remotely monitored.
All 154 consecutive patients (100 males, 63 ± 15 year-old) who received the Reveal LINQTM ILR during the period July 2014-June 2016 were enrolled. The device was implanted in a procedure room and all patients where provided with the MyCareLinkTM remote monitoring system. Data were reviewed every working day via the Carelink® web system by a specialist nurse who, in case of significant events, consulted an electrophysiologist. During a mean follow-up of 12.1 (6.7-18.4) months (range 2-24 months), a diagnosis was made in 99 (64%) patients and in 60 (39%) ≥1 therapeutic interventions were established following recording of arrhythmias. In 26 of these 60 patients, remote monitoring prompted therapeutic interventions following asymptomatic arrhythmic events 3.8 months before the next theoretical scheduled in-office data download. False bradycardia detection for undersensing occurred in 44 (29%) patients and false tachycardia detection for oversensing in 4 (3%). One patient experienced skin erosion requiring explantation and none suffered from infection.
The remote monitoring feature of the Reveal LINQTM allowed earlier diagnosis of asymptomatic but serious arrhythmias in a significant proportion of patients. Implantation of the device outside the EP laboratory appeared safe. However, R-wave undersensing and consequent false recognition of bradyarrhythmias remains a clinically important technical issue.
当需要进行延长的心脏节律监测时,植入式循环记录器 (ILR) 适用于多种临床情况。我们旨在评估新的美敦力 Reveal LINQTM ILR 的临床影响、安全性和准确性,该设备可在电生理 (EP) 实验室外插入并进行远程监测。
2014 年 7 月至 2016 年 6 月期间,连续收治了 154 例接受 Reveal LINQTM ILR 植入的患者(100 例男性,63±15 岁)。该设备在一个手术室内植入,所有患者均配备了 MyCareLinkTM 远程监测系统。一名专科护士每天通过 Carelink®网络系统查看数据,如果有重要事件,会咨询电生理学家。在平均 12.1(6.7-18.4)个月(2-24 个月)的随访期间,99 例(64%)患者得到诊断,60 例(39%)≥1 例患者在记录心律失常后进行了治疗干预。在这 60 例患者中,26 例患者在无症状心律失常事件发生后 3.8 个月,通过远程监测提示进行治疗干预,这早于下一次理论上预定的门诊数据下载时间。44 例(29%)患者出现因检测到 R 波不足而导致的假性心动过缓检测,4 例(3%)患者出现因检测到 R 波过度而导致的假性心动过速检测。1 例患者出现皮肤侵蚀,需要取出装置,无一例患者发生感染。
Reveal LINQTM 的远程监测功能使相当一部分无症状但严重心律失常的患者能够更早地得到诊断。该设备在 EP 实验室外植入是安全的。然而,R 波检测不足以及由此导致的假性心动过缓识别仍然是一个重要的临床技术问题。